Xenthera, Inc. Overview
Xenthera, headquartered in Salt Lake City Utah is a private clinical stage biopharmaceutical company founded in 2022, focused on oncology, discovering, and developing novel therapeutics for solid tumor oncology targets to improve the lives of patients fighting cancer. The leadership team has a strong record of developing drugs and devices from discovery through commercialization including multiple successful exits as well as extensive trial design and execution experience. Xenthera’s lead drug is XT-0528, an oral small molecule ROR𝛾T inverse agonist with robust human safety data where the Phase I dosing study in patients with advanced recurrent or metastatic solid tumors has been initiated. Xenthera’s business model is to remain lean with an experienced team and recognized scientific advisors. ROR𝛾T expression is increased in human pancreatic cancer cells and blockade limits tumor growth in both cellular and mouse models. In addition, blockade of ROR𝛾T has been shown to prevent toxicity of immune modulated colitis in a recognized animal model. Since XT-0528 reduces IL-17 and inflammatory signaling it is hypothesized to alter the tumor microenvironment to enable IO therapies to work more effectively while lowering toxicity and serious side effects.
Address: 1865 West 2100 South, Suite 100, Salt Lake City Utah 84119